Haemostasis Research Group, Institute of Molecular Medicine, Trinity College, Dublin, Ireland.
Haemophilia. 2010 Jan;16(1):3-13. doi: 10.1111/j.1365-2516.2009.02005.x. Epub 2009 Apr 16.
The interaction of factor VIII (FVIII) with von Willebrand Factor (VWF) is of direct clinical significance in the diagnosis and treatment of patients with haemophilia A and von Willebrand disease (VWD). A normal haemostatic response to vascular injury requires both FVIII and VWF. It is well-established that in addition to its role in mediating platelet to platelet and platelet to matrix binding, VWF has a direct role in thrombin and fibrin generation by acting as a carrier molecule for the cofactor FVIII. Recent studies show that the interaction affects not only the biology of both FVIII and VWF, and the pathology of haemophilia and VWD, but also presents opportunities in the treatment of haemophilia. This review details the mechanisms and the molecular determinants of FVIII interaction with VWF, and the role of FVIII-VWF interaction in modulating FVIII interactions with other proteases, cell types and cellular receptors. The effect of defective interaction of FVIII with VWF as a result of mutations in either protein is discussed.
因子 VIII(FVIII)与血管性血友病因子(VWF)的相互作用在血友病 A 和血管性血友病(VWD)患者的诊断和治疗中具有直接的临床意义。正常的止血反应需要 FVIII 和 VWF。众所周知,除了在介导血小板与血小板和血小板与基质结合中的作用外,VWF 还通过作为 FVIII 辅因子的载体分子,直接参与凝血酶和纤维蛋白原的生成。最近的研究表明,这种相互作用不仅影响 FVIII 和 VWF 的生物学特性以及血友病和 VWD 的病理学特性,而且在血友病的治疗中也提供了机会。本综述详细介绍了 FVIII 与 VWF 相互作用的机制和分子决定因素,以及 FVIII-VWF 相互作用在调节 FVIII 与其他蛋白酶、细胞类型和细胞受体相互作用中的作用。讨论了由于两种蛋白质中的突变导致 FVIII 与 VWF 相互作用缺陷的影响。